Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis. Lancet 2020; 395: 1487-1495.
Published: 22nd July 2020
Authors: Chiarito M, Sanz-Sanchez J, Cannata F, Cao D, Sturla M, Panico C et al.
There were nine RCTs that included over 42,000 patients. Compared with aspirin, use of a P2Y12 inhibitor (usually clopidogrel) had a borderline improvement in reducing myocardial infarction (odds ratio 0.81, 95 per cent confidence interval 0.66 to 0.99), but other effects on risk reduction (for stroke, death and vascular death) were similar.Pubmed Link
You may also be interested in
Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N Engl J Med 2020; 383: 207-217.
Authors: Claiborne Johnston S, Amarenco P, Denison H, Evans SR, Himmelmann A, James S et al.
Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med 2020; 382: 1994-2004.
Authors: Bonaca MP, Bauersachs RM, Anand S, Debus ES, Nehler MR, Patel MR et al.
Rivaroxaban with or without aspirin in patients with heart failure and chronic coronary or peripheral artery disease. The COMPASS Trial. Circulation 2019; 140: 529-537
Authors: Branch KR, Probstfield JL, Eikelboom JW, Bosch J, Maggioni AP, Cheng RK et al.
No clinical benefit of intramuscular delivery of bone marrow-derived mononuclear cells in nonreconstructable peripheral arterial disease: results of a phase-III randomized-controlled trial. Ann Surg 2018; 268: 756-761.
Authors: Lindeman J, Zwaginga J, Kallenberg-Lantrua G, van Wissen RC, Schepers A, van Bockel HJ et al.
A systematic review of the efficacy of aspirin monotherapy versus other antiplatelet therapy regimens in peripheral arterial disease. J Vasc Surg 2018; 67: 1922-1932.
Authors: Beiswenger AC, Jo A, Harth K, Kumins NH, Shishehbor MH, Kashyap VS et al.
Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med 2018; 379: 215-225.
Authors: Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ et al.
Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet 2018; 392: 387–399.
Authors: Rothwell PM, Cook NR, Gaziano JM, Price JF, Belch JFF, Roncaglioni MC et al.
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2018; 391: 219-229.
Authors: Anand S, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P et al.
Efficacy and safety of aspirin in patients with peripheral vascular disease: an updated systematic review and meta-analysis of randomized controlled trials. PLoS ONE 2017; 12: e0175283.
Authors: Mahmoud AN, Elgendy AY, Rambarat C, Mahtta D, Elgendy IY, Bavry AA et al.
Evaluation of cell therapy on exercise performance and limb perfusion in peripheral artery disease. Circulation. 2017; 135: 1417-1428.
Authors: Perin EC, Murphy MP, March KL, Bolli R, Loughran J, Yang PC et al.
Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017; 377: 1319-1330.
Authors: Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O et al.
Efficacy and safety of alprostadil in patients with peripheral arterial occlusive disease Fontaine stage IV: results of a placebo-controlled randomized multicenter trial (ESPECIAL). Eur J Vasc Endovasc Surg 2017; 53: 559-566.
Authors: Lawall H, Pokrovsky A, Checinski P, Ratushnyuk A, Hamm G, Randerath O et al.